Form 8-K - Current report:
SEC Accession No. 0001104659-23-041009
Filing Date
2023-04-03
Accepted
2023-04-03 17:28:40
Documents
17
Period of Report
2023-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2311180d2_8k.htm   iXBRL 8-K 32303
2 EXHIBIT 1.1 tm2311180d2_ex1-1.htm EX-1.1 245252
3 EXHIBIT 5.1 tm2311180d2_ex5-1.htm EX-5.1 17478
7 GRAPHIC tm2311180d2_ex5-1img03.jpg GRAPHIC 3224
8 GRAPHIC tm2311180d2_ex5-1img02.jpg GRAPHIC 2794
9 GRAPHIC tm2311180d2_ex5-1img01.jpg GRAPHIC 2794
  Complete submission text file 0001104659-23-041009.txt   550119

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA anvs-20230331.xsd EX-101.SCH 3039
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20230331_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20230331_pre.xml EX-101.PRE 22599
11 EXTRACTED XBRL INSTANCE DOCUMENT tm2311180d2_8k_htm.xml XML 3707
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 23794034
SIC: 2834 Pharmaceutical Preparations